Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Type 2 Diabetes and its Treatm...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Type 2 Diabetes and its Treatment with Linagliptin are both Associated with Elevated Mortality in Bullous Pemphigoid

Type 2 Diabetes and its Treatment with Linagliptin are both Associated with Elevated Mortality in Bullous Pemphigoid

Abstract is missing (Short communication)

Bibliographic Details
Main Authors: Päivi Leisti, Anna Pankakoski, Jari Jokelainen, Laura Huilaja, Jaana Panelius, Kaisa Tasanen, Outi Varpuluoma
Format: Article
Language:English
Published: Medical Journals Sweden 2024-09-01
Series:Acta Dermato-Venereologica
Subjects:
Bullous pemphigoid
epidemiology
gliptin
dipeptidyl-4 peptidase
mortality
Online Access:https://medicaljournalssweden.se/actadv/article/view/40645
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://medicaljournalssweden.se/actadv/article/view/40645

Similar Items

  • Linagliptin-Associated Alopecia and Bullous Pemphigoid
    by: Ali Someili, et al.
    Published: (2019-09-01)
  • Accurate diagnosis of bullous pemphigoid requires multiple health care visits
    by: Päivi Leisti, et al.
    Published: (2023-11-01)
  • The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study
    by: Vaia Lambadiari, et al.
    Published: (2021-02-01)
  • Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients
    by: Antti Nätynki, et al.
    Published: (2022-07-01)
  • Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
    by: Dana Shalmon, et al.
    Published: (2024-04-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs